Creation of QUALIblood
QUALIblood S.A. was created on the 15th of November 2017. There are 3 categories of investors: founders, private and institutional. This society was created to help the pharmaceutical and IVD companies in developing innovant medicines or biomarkers to finally improve public health.
Installation of the laboratory facilities
Several analysers were acquired. These will permit QUALIblood to investigate many blood biomarkers and start their own development of innovative biomarkers and devices.
First contracts and experiments for Bioxodes and Diagnostica Stago
Subvention for the development of the ETP-based APC resistance
QUALIblood has received public funds for the development and the validation of the ETP-based APC resistance assay. This assay is a legal requirement for the development of steroid contraceptive. QUALIblood is the first company having validated the ETP-based APC resistance.
Publication of the results of our first innovative biomarker
Our publication on the “Validation of the ETP-based APC resistance test for the clinical investigation of steroid contraceptive in women: an unmet clinical en regulatory need” in Clinical Chemistry and Laboratory Medicines.
International Award
The CSO of Qualiblood get the Eberhard F. Mammen Young Investigator Award for the work on the ETP-based APC resistance presented in July at the ISTH.
Publication of the results of our first innovative biomarker
Our publication on the “Validation of the ETP-based APC resistance test for the clinical investigation of steroid contraceptive in women: an unmet clinical and regulatory need” has been published in Clinical Chemistry and Laboratory Medicines.
International Award
The CSO of QUALIblood got the Eberhard F. Mammen Young Investigator Award for the work on the ETP-based APC resistance presented in July at the ISTH meeting.
A PhD candidate at Qualiblood
Qualiblood has received a grant to support and develop the further development of the ETP-based APC resistance assay under the project named “Hormone-induced Coagulopathy”. This project is granted for a 4-years period.
License agreement for the DP-Filter(r)
QUALIblood has signed a license agreement with the University of Namur for the DP-Filter(r), an IVD medical device able to remove a class of drugs named “direct oral anticoagulants” or “DOACs” from plasma samples of patients treated with these drugs. This will help hemostasis laboratories in avoiding multiple interferences due to these compounds. QUALIblood has provided support for the conception and the design of the DP-Filter since 2018.
Master Service Agreement signed with a Japanese pharmaceutical company involved in women’s health
First MSA for QUALIblood with a leading pharmaceutical company involved in women’s health and contraception. The global hormonal contraceptive market is expected to reach USD 19.31 Billion in 2017 to USD 31.07 Billion by 2025.
QUALIblood provides analytical services for the investigations of the thrombogenicity induced by hormonal contraceptive therapies.
QUALIblood grants a Distributorship agreement to 5-Diagnostics for the commercialization of the DP-Filter worldwide
5-Diagnostics is rapidly establishing its presence on the global diagnostic market: Headquartered in Switzerland and with a strong US base, 5-Diagnostics employs a centrally managed, global network of dedicated hemostasis sales representatives and product specialists. Each of these have years of proven expertise in meeting the needs of a wide range of customers, including clinical, research and industry based groups.